Literature DB >> 18312363

Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report.

M Franchini, G Gandini, A Giuffrida, M De Gironcoli, A B Federici.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18312363     DOI： 10.1111/j.1365-2516.2008.01668.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  6 in total

Review 1.  Alloantibodies in von Willebrand disease.

Authors:  Paula D James; David Lillicrap; Pier M Mannucci
Journal:  Blood       Date:  2013-01-07       Impact factor: 22.113

2.  Evidence-based recommendations on the treatment of von Willebrand disease in Italy.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini; Giancarlo Castaman; Augusto B Federici
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

3.  Successful Desensitization of a Patient with Possible IgE-Mediated Anaphylactic Reaction to FVIII/VWF Concentrate.

Authors:  Burcin Beken; Velat Celik; Pinar Gokmirza Ozdemir; Tuba Eren; Mehtap Yazicioglu
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-06-17       Impact factor: 1.349

Review 4.  Principles of care for the diagnosis and treatment of von Willebrand disease.

Authors:  Giancarlo Castaman; Anne Goodeve; Jeroen Eikenboom
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

5.  Rare Occurrence of Inhibitors in Von Willebrand Disease: A Case Report.

Authors:  Bipin P Kulkarni; Kirti Ghargi; Chandrakala Shanmukhaiah; Shrimati D Shetty
Journal:  Front Med (Lausanne)       Date:  2022-01-11

Review 6.  Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A.

Authors:  Giancarlo Castaman; Silvia Linari
Journal:  Ther Clin Risk Manag       Date:  2016-06-30       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.